279 related articles for article (PubMed ID: 30517641)
1. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting.
Abad L; Tafani V; Tasse J; Josse J; Chidiac C; Lustig S; Ferry T; Diot A; Laurent F; Valour F
J Antimicrob Chemother; 2019 Mar; 74(3):625-632. PubMed ID: 30517641
[TBL] [Abstract][Full Text] [Related]
2. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
[TBL] [Abstract][Full Text] [Related]
3. Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.
Abad L; Josse J; Tasse J; Lustig S; Ferry T; Diot A; Laurent F; Valour F
J Antimicrob Chemother; 2020 Jun; 75(6):1466-1473. PubMed ID: 32125419
[TBL] [Abstract][Full Text] [Related]
4. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
Werth BJ
J Antimicrob Chemother; 2017 May; 72(5):1410-1414. PubMed ID: 28158617
[TBL] [Abstract][Full Text] [Related]
5. Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison.
Peñuelas M; Candel FJ; Lejarraga C; López-González L; Viñuela-Prieto JM; López de Mendoza D
Rev Esp Quimioter; 2016 Oct; 29(5):255-8. PubMed ID: 27374726
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
Rodríguez-Avial I; Culebras E; Betriu C; Morales G; Pena I; Picazo JJ
J Antimicrob Chemother; 2012 Jan; 67(1):167-9. PubMed ID: 21954458
[TBL] [Abstract][Full Text] [Related]
7. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.
Keel RA; Tessier PR; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504
[TBL] [Abstract][Full Text] [Related]
10. Subinhibitory concentrations of tedizolid potently inhibit extracellular toxin production by methicillin-sensitive and methicillin-resistant Staphylococcus aureus.
Katahira EJ; Davidson SM; Stevens DL; Bolz DD
J Med Microbiol; 2019 Feb; 68(2):255-262. PubMed ID: 30556803
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of tedizolid and other comparator drugs in methicillin-resistant Staphylococcus aureus isolates in skin and soft tissue infections in seven Colombian hospitals.
Leal AL; Ovalle MV; Cortés JA; Montañes AM; De la Rosa ZR; Rodríguez JY; Gualtero S; Ariza B; Sussman O; Torres MDP
Biomedica; 2018 Dec; 38(4):507-513. PubMed ID: 30653864
[TBL] [Abstract][Full Text] [Related]
12. Comparative
Wang S; Li Y; Xue F; Liu J; Yang W; Zhang J; Glenschek-Sieberth M; Lyu Y
J Chemother; 2019 Oct; 31(6):313-319. PubMed ID: 31215343
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant
Hasannejad-Bibalan M; Mojtahedi A; Biglari H; Halaji M; Sedigh Ebrahim-Saraie H
Microb Drug Resist; 2019 Nov; 25(9):1330-1337. PubMed ID: 31290721
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States.
Farrell DJ; Mendes RE; Bensaci M
Diagn Microbiol Infect Dis; 2019 Jan; 93(1):85-88. PubMed ID: 30314652
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
[TBL] [Abstract][Full Text] [Related]
17. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).
Carvalhaes CG; Sader HS; Flamm RK; Mendes RE
J Antimicrob Chemother; 2019 Jul; 74(7):1928-1933. PubMed ID: 30932152
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.
Biedenbach DJ; Bouchillon SK; Johnson B; Alder J; Sahm DF
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1933-1939. PubMed ID: 27677280
[TBL] [Abstract][Full Text] [Related]
19. Differences in oxazolidinone resistance mechanisms and small colony variants emergence of
Staudacher M; Hotz JF; Kriz R; Schefberger K; Schneider L; Spettel K; Starzengruber P; Hagemann JB; Leutzendorff A; Burgmann H; Lagler H
Emerg Microbes Infect; 2024 Dec; 13(1):2292077. PubMed ID: 38055244
[TBL] [Abstract][Full Text] [Related]
20. Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients.
Roch M; Varela MC; Taglialegna A; Rosato AE
J Antimicrob Chemother; 2020 Jan; 75(1):126-134. PubMed ID: 31617901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
